Back to News
Market Impact: 0.48
Liquidia slumps after US court rules for United Therapeutics in patent fight
Source: reuters.com
Legal & LitigationPatents & Intellectual PropertyHealthcare & Biotech
Liquidia shares plunged nearly 50% after a federal judge ruled that its lung drug infringes a key United Therapeutics patent. The decision materially undermines the drug's commercial outlook and creates a significant legal and competitive setback for Liquidia.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.82
Ticker Sentiment
LQDA-0.92
UTHR0.62
More News
- United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
- US judge approves settlement allowing Paramount to acquire Warner Bros
- Why is Nidec stock plunging today?
- Nidec Corp shares slump after auditor declines to sign off on earnings
- US judge allows Paramount to close Warner Bros acquisition
- OpenAI is sued over rogue AI Hugging Face cyberattack